CIRM grants support promising stem cell-based projects; include two CNSI Magnify incubator start-ups

The California Institute for Regenerative Medicine recently approved a $44.1 million investment in 11 projects as part of the Translational Research Program (TRAN). The awardees include two start-up companies from the Magnify incubator at CNSI, MyoGene Bio and ImmunoVec.

The goal of TRAN’s research funding is to support promising stem cell-based projects that
accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

“Our goal at Magnify is to help start-ups succeed by accelerating their access to facilities, resources and funding,” said Nikki Lin, director of entrepreneurship & commercialization for the CNSI, also overseeing the Magnify incubator. “We extend our congratulations to the MyoGene Bio and ImmunoVec teams who with this funding will be able to take the next step on promising research that can impact the greater public good.”

The TRAN research projects for MyoGene Bio and ImmunoVec include:

MyoGene Bio: “Development of a gene editing therapy for Duchenne muscular dystrophy.” Principal investigator: Courtney Young

ImmunoVec: “Hematopoietic Stem Cell Gene Therapy for Immunodysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) Syndrome.” Principal investigator: Kate Masiuk

Information on the CIRM grant awards can be found at: https://www.cirm.ca.gov/about-cirm/newsroom/press-releases/11232021/stem-cell-agency-board-invests-therapy-targeting-deadly

For more information on Magnify and its portfolio companies, please visit: https://magnify.cnsi.ucla.edu/